Julien Taı̈eb

43.5k total citations · 11 hit papers
663 papers, 19.8k citations indexed

About

Julien Taı̈eb is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Julien Taı̈eb has authored 663 papers receiving a total of 19.8k indexed citations (citations by other indexed papers that have themselves been cited), including 421 papers in Oncology, 178 papers in Pulmonary and Respiratory Medicine and 171 papers in Pathology and Forensic Medicine. Recurrent topics in Julien Taı̈eb's work include Colorectal Cancer Treatments and Studies (301 papers), Genetic factors in colorectal cancer (149 papers) and Gastric Cancer Management and Outcomes (111 papers). Julien Taı̈eb is often cited by papers focused on Colorectal Cancer Treatments and Studies (301 papers), Genetic factors in colorectal cancer (149 papers) and Gastric Cancer Management and Outcomes (111 papers). Julien Taı̈eb collaborates with scholars based in France, Italy and United States. Julien Taı̈eb's co-authors include Magali Terme, Pierre Laurent‐Puig, Rénato Fanchin, Simon Pernot, Éric Tartour, Aziz Zaanan, Takayuki Yoshino, Thierry André, Elie Marcheteau and René Frydman and has published in prestigious journals such as New England Journal of Medicine, Physical Review Letters and Journal of Biological Chemistry.

In The Last Decade

Julien Taı̈eb

621 papers receiving 19.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

2015 883 citations Orianne Colussi, Elie Marcheteau et al. profile →
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 774 citations Julien Taı̈eb, Jenny F. Seligmann et al. Annals of Oncology profile →
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

2005 760 citations Christophe Louvet, Thierry André et al. Journal of Clinical Oncology profile →
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 736 citations Josep Tabernero, Ramón Salazar et al. Annals of Oncology profile →
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

2016 653 citations Julien Taı̈eb et al. profile →
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

2012 522 citations Magali Terme, Simon Pernot et al. Cancer Research profile →
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

2018 372 citations Eric Van Cutsem, Lucjan Wyrwicz et al. Annals of Oncology profile →
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

2023 183 citations Gerald W. Prager, Julien Taı̈eb et al. profile →
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

2023 163 citations Marwan Fakih, Lisa Salvatore et al. profile →
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment

2022 147 citations Julien Taı̈eb, Romain Cohen et al. European Journal of Cancer profile →
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers

2025 13 citations Jenny F. Seligmann, Julien Taı̈eb et al. profile →

Peers

Countries citing papers authored by Julien Taı̈eb

Since Specialization

Citations

This map shows the geographic impact of Julien Taı̈eb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Taı̈eb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Taı̈eb more than expected).

Fields of papers citing papers by Julien Taı̈eb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Taı̈eb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Taı̈eb. The network helps show where Julien Taı̈eb may publish in the future.

Co-authorship network of co-authors of Julien Taı̈eb

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Taı̈eb. A scholar is included among the top collaborators of Julien Taı̈eb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Taı̈eb. Julien Taı̈eb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer 2025 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih	7
2	Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study 2024 ·European Journal of Cancer ·Atsuo Takashima, Pilar García‐Alfonso, (unknown), Ali Ayberk Beşen, Yong Sang Hong, Pieter‐Jan Cuyle, Patricio Yañez, Matthew Burge, Takayuki Yoshino, Tae Won Kim, Karen Cui, (unknown), Rishi Jain, David E. Adelberg, Julien Taı̈eb	7
3	Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial 2024 ·ESMO Open ·Josep Tabernero, Julien Taı̈eb, Marwan Fakih, Gerald W. Prager, Eric Van Cutsem, Fortunato Ciardiello, R. Mayer, Nadia Amellal, (unknown), Elizabeth Calleja, Takayuki Yoshino	4
4	35P Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial 2024 ·Annals of Oncology ·Gerald W. Prager, Josep Tabernero, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, (unknown), Weirong Yao, (unknown), Julien Taı̈eb	1
5	517P Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), Aurélia Meurisse, Pascal Artru, Thierry Lecomte, (unknown), Romain Coriat, (unknown), Romain Cohen, (unknown), Samy Louafi, Jean‐Baptiste Bachet, Julien Taı̈eb, Déwi Vernerey, (unknown), Pierre Laurent‐Puig	1
6	Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer 2024 ·Clinics and Research in Hepatology and Gastroenterology ·Hampig Raphaël Kourié, (unknown), (unknown), (unknown), Lewis Nasr, Fadi El Karak, (unknown), (unknown), (unknown), Nizar Bitar, (unknown), (unknown), Fadi Farhat, Jawad A. Makarem, Joseph Kattan, Julien Taı̈eb	1
7	A systematic review of minimal length of lroximal margin in gastric adenocarcinoma resection 2023 ·Langenbeck s Archives of Surgery ·Antoine Mariani, Aziz Zaanan, Lionel Rebibo, Grégory Martin, Julien Taı̈eb, (unknown)	2
8	651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study 2023 ·Annals of Oncology ·Christophe Borg, V. Vendrely, (unknown), Thierry André, (unknown), (unknown), Simon Pernot, O. Bouché, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Éric François, Julien Taı̈eb, Karine Le Malicot, Déwi Vernerey, Aurélia Meurisse, Stéfano Kim	1
9	P-95 Long-term effectiveness results and prognostic predictors for overall survival from CIREL – the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM 2023 ·Annals of Oncology ·Hans Prenen, Dirk Arnold, Bruno Sangro, Bleranda Zeka, (unknown), (unknown), Roberto Iezzi, Philippe L. Pereira, Julien Taı̈eb	0
10	625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study 2023 ·Annals of Oncology ·Claire Gallois, (unknown), Édouard Auclin, Elisabeth Bergen, Simon Pernot, (unknown), Isabelle Trouilloud, Yann Touchefeu, Anthony Turpin, Thibault Mazard, Lorenzo Pilla, (unknown), (unknown), (unknown), Chloé Melchior, Pascal Artru, Sebastian Stintzing, Olivier Dubreuil, David Tougeron, Julien Taı̈eb	4
11	P-386 Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer 2023 ·Annals of Oncology ·Harpreet Wasan, Sara Lonardi, Jayesh Desai, Gunnar Folprecht, Claire Gallois, (unknown), Shahid A. Khan, (unknown), Julien Taı̈eb	1
12	Nutrition support in pancreatic cancer: An expert statement on practical implementation of French guidelines 2023 ·Clinics and Research in Hepatology and Gastroenterology ·Julien Taı̈eb, (unknown), Ronan Thibault, Patrick Pessaux, (unknown), (unknown), (unknown)	2
13	Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies 2023 ·Lucjan Wyrwicz, Julien Taı̈eb, Timothy Price, (unknown), Meinolf Karthaus, Loïck Vidot, (unknown), Timo Reisländer, (unknown), Volker Heinemann	1
14	FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty 2022 ·ESMO Open ·(unknown), Oliver Todd, Peter Hall, (unknown), Aaron Quyn, Michel Seymour, Michael Braun, Jeanine M.L. Roodhart, Cornelis J.A. Punt, (unknown), Julien Taı̈eb, Mehdi Karoui, Julia Brown, David A. Cairns, Dion Morton, Alexandra Gilbert, Jenny F. Seligmann	5
15	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer 2021 ·Clinical Cancer Research ·Laëtitia Marisa, Yuna Blum, Julien Taı̈eb, Mira Ayadi, Camilla Pilati, Karine Le Malicot, Côme Lepage, Ramón Salazar, Daniela Aust, Alex Duval, Hélène Blons, Valérie Taly, David Gentien, Audrey Rapinat, Janick Sèlves, Sophie Mouillet‐Richard, Valérie Boige, Jean‐François Emile, Aurélien de Reyniès, Pierre Laurent‐Puig	37
16	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial 2021 ·Clinical Cancer Research ·Julien Taı̈eb, Valérie Taly, Julie Henriques, (unknown), Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepère, May Mabro, Joëlle Egreteau, Olivier Bouché, Claire Mulot, (unknown), Kariman Chaba, Thibault Mazard, Aimery de Gramont, Déwi Vernerey, Thierry André, Pierre Laurent‐Puig	71
17	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy 2018 ·Clinical Cancer Research ·Claire Gallois, Julien Taı̈eb, Delphine Le Corre, Karine Le Malicot, Josep Tabernero, Claire Mulot, Jean‐François Seitz, Thomas Aparicio, Gunnar Folprecht, Côme Lepage, Enrico Mini, Jean‐Luc Van Laethem, Jean‐François Emile, Pierre Laurent‐Puig	24
18	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) 2017 ·Clinical Cancer Research ·Fanny Garlan, Pierre Laurent‐Puig, David Sefrioui, Nathalie Siauve, Audrey Didelot, Nasrin Sarafan‐Vasseur, Pierre Michel, Géraldine Perkins, Claire Mulot, Hélène Blons, Julien Taı̈eb, Frédéric Di Fiore, Valérie Taly, Aziz Zaanan	165
19	VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer breakdown → 2012 ·Cancer Research ·Magali Terme, Simon Pernot, Elie Marcheteau, Federico Sandoval, Nadine Benhamouda, Orianne Colussi, Olivier Dubreuil, Alain Carpentier, Éric Tartour, Julien Taı̈eb	522
20	Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy 2011 ·Clinical Cancer Research ·Aziz Zaanan, Jean–François Fléjou, Jean‐François Emile, (unknown), Peggy Cuillière-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, Julien Taı̈eb	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact